Skip to main content
. Author manuscript; available in PMC: 2023 Mar 1.
Published in final edited form as: J Control Release. 2022 Jan 22;343:267–276. doi: 10.1016/j.jconrel.2022.01.024

Figure 6: Antitumor efficacy of intratumoral ELP-K12/CpG.

Figure 6:

(A) Average size of 4T1 untreated tumors or tumors treated i.t. with 50 μg or 100 μg CpG complexed with ELP-K12 through the first 13 days post-treatment (n=4). (B) Number of metastases in dissected lungs from mice for each treatment group at day 13 post-treatment (n=4). *p<0.05 (ANOVA, Tukey)